Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

The immune system's hidden talents

Half of the immune system has a hidden talent, researchers at Washington University School of Medicine in St. Louis have discovered.

27 Jan 2009

Gene therapy for rheumatoid arthritis: promising results

Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past.

27 Jan 2009

Although our genetics differ significantly, we all look alike...

The genetic variation within a species can be significant, but very little of that variation results in clear differences in morphology or other phenotypes.

27 Jan 2009

Unexpected finding opens up new way to stop autoimmune diseases and transplant rejection

After several years of battling recurring infections, the last thing a patient and her doctors ever expected was that the cause of her problems might actually help millions live longer, more active lives.

23 Jan 2009

Poxvirus breakthrough

Smallpox has a nasty history throughout the world.

19 Jan 2009

Women suffer more from rheumatoid arthritis

Tuulikki Sokka from the Jyvaskyla Central Hospital, Finland, along with other members of the Quantitative Standard Monitoring of Patients with RA (QUEST-RA) program, explored possible associations between gender and disease activity measures, treatments, and clinical characteristics in more than 6,000 RA patients from 70 sites in 25 countries.

13 Jan 2009

New folate antagonists selectively target pathway important in rheumatoid arthritis

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis.

13 Jan 2009

Researchers trick bone marrow into releasing mesenchymal stem cells

Scientists have tricked bone marrow into releasing extra adult stem cells into the bloodstream, a technique that they hope could one day be used to repair heart damage or mend a broken bone, in a new study published today in the journal Cell Stem Cell.

9 Jan 2009

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009

Adults with asthma at increased risk of serious pneumococcal disease

Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia.

22 Dec 2008

Research highlights recognized disease risks associated with vitamin D deficiency

Once believed to be important only for bone health, vitamin D is now seen as having a critical function in maintaining the immune system throughout life.

17 Dec 2008

Lessons from Northwick Park drug-trial disaster

Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead.

From The University of Manchester 15 Dec 2008

Gene therapy used to treat periodontal disease

Scientists at the University of Michigan have shown that gene therapy can be used to successfully stop the development of periodontal disease, the leading cause of tooth loss in adults.

12 Dec 2008

Mathematical models of adaptive immunity

More than five million people die every year from infectious diseases, despite the availability of numerous antibiotics and vaccines. The discovery of penicillin to treat bacterial infections, along with the development of vaccines for previously incurable virus diseases such as polio and smallpox, achieved great reductions in mortality during the mid-20th century.

11 Dec 2008

Experimental drug successfully blocks mutation in bone marrow cancers

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

10 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008